



VWD1 A, WAVELENGTH=215 nm (U:\MICHELH\DATA\HM050102\011-0101.D)



A) PEG-T1249

VWD1 A, WAVELENGTH=215 nm (U:\MICHELH\DATA\HM050102\012-0201.D)



B) T1249

FIG. 1









FIG. 2




CYCLE 6-RESIDUE 4




CYCLE 7-RESIDUE 5



CYCLE 8-RESIDUE 6



CYCLE 9-RESIDUE 7



CYCLE 10-RESIDUE 8






FIG. 3A




CYCLE 1:BLANK 1




CYCLE 2:STANDARD 1



CYCLE 3:RESIDUE 1



CYCLE 4:RESIDUE 2



CYCLE 5:RESIDUE 3




FIG. 3B



CONCENTRATION-TIME PROFILE OF mPEG20K-CMAB-T1249 IN RATS AFTER A SINGLE SUBCUTANEOUS ADMINISTRATION AT 8




FIG. 4

PLASMA PHARMACOKINETICS FOR T-1249 ADMINISTERED BY SUBCUTANEOUS OR INTRAVENOUS INJECTION TO RATS.




FIG. 5




FIG. 6